| Not Yet Recruiting | Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer NCT07415005 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib NCT07486648 | Shanxi Province Cancer Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC NCT07392073 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemother NCT07222566 | Pfizer | Phase 3 |
| Recruiting | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor a NCT07185997 | ArriVent BioPharma, Inc. | Phase 3 |
| Recruiting | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previ NCT06908993 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Not Yet Recruiting | HS-IT101 Injection for Advanced NSCLC NCT07105176 | Qingdao Sino-Cell Biomedicine Co., Ltd. | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | SSGJ-707 in Advanced Non-Small Cell Lung Cancer NCT06980272 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 3 |
| Recruiting | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 |
| Not Yet Recruiting | Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function NCT06823245 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer NCT06731413 | Virginia Commonwealth University | Phase 2 |
| Not Yet Recruiting | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study NCT06775483 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Withdrawn | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatmen NCT06434103 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyros NCT06585059 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, i NCT06452277 | Bayer | Phase 3 |
| Recruiting | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer NCT05777603 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken To NCT06360211 | Bayer | Phase 1 |
| Completed | A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When The NCT06348888 | Bayer | Phase 1 |
| Completed | A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Togeth NCT06378658 | Bayer | Phase 1 |
| Completed | A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These NCT06329895 | Bayer | Phase 1 |
| Active Not Recruiting | Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Adv NCT06269133 | Regeneron Pharmaceuticals | — |
| Completed | A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants NCT06221475 | Bayer | Phase 1 |
| Recruiting | Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG NCT06107374 | CellSight Technologies, Inc. | Phase 2 |
| Recruiting | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973 | Qianfoshan Hospital | Phase 3 |
| Unknown | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer NCT05978401 | Guangzhou Gloria Biosciences Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 | Akeso | Phase 1 / Phase 2 |
| Not Yet Recruiting | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC NCT05910034 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Ad NCT05785767 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Active Not Recruiting | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic NCT05607550 | ArriVent BioPharma, Inc. | Phase 3 |
| Active Not Recruiting | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combinati NCT05557591 | Regeneron Pharmaceuticals | Phase 2 |
| Terminated | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer NCT05652868 | Mythic Therapeutics | Phase 1 |
| Active Not Recruiting | Study With Various Immunotherapy Treatments in Participants With Lung Cancer NCT05676931 | Gilead Sciences | Phase 2 |
| Active Not Recruiting | AK112 in Advanced Non-Small Cell Lung Cancer NCT05499390 | Akeso | Phase 3 |
| Unknown | Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) NCT03334864 | Peking Union Medical College Hospital | — |
| Unknown | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer NCT05489731 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Ca NCT05504278 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small NCT05482568 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer NCT05416775 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer NCT05420220 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Active Not Recruiting | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activat NCT05364073 | ArriVent BioPharma, Inc. | Phase 1 |
| Completed | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma NCT05303493 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Active Not Recruiting | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lu NCT05318573 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 2 |
| Recruiting | Lifei Xiaoji Wan in Treatment of Advanced NSCLC NCT06406166 | Henan University of Traditional Chinese Medicine | N/A |
| Terminated | Long-Term Follow-Up Study of Patients Receiving ATL001 NCT04785365 | Achilles Therapeutics UK Limited | Phase 2 |
| Unknown | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Canc NCT05004974 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Phase 2 |
| Active Not Recruiting | A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer NCT05215067 | Akeso | Phase 2 |
| Unknown | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Pa NCT05287386 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Unknown | Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer NCT04755738 | Qianfoshan Hospital | Phase 2 |
| Terminated | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent NCT05001724 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 / Phase 3 |
| Active Not Recruiting | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With M NCT05099172 | Bayer | Phase 1 / Phase 2 |
| Unknown | Tislelizumab as Cross-line Treatment for Advanced NSCLC NCT05192681 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer NCT05435274 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) NCT04990063 | suhaichuan | Phase 1 |
| Unknown | Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer NCT04922658 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 2 |
| Active Not Recruiting | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer NCT04940325 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Unknown | A Phase 1/2 Study of SC-43 in Combination With Cisplatin NCT04733521 | RaND Biosciences | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer NCT04818333 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC NCT04886401 | University Hospital, Brest | — |
| Active Not Recruiting | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KR NCT04685135 | Mirati Therapeutics Inc. | Phase 3 |
| Active Not Recruiting | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Ca NCT04699123 | Yale University | Phase 2 |
| Unknown | Efficacy of Osimertinib in Patients With Lung Cancer NCT06174857 | Hunan Province Tumor Hospital | — |
| Recruiting | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib NCT04613596 | Mirati Therapeutics Inc. | Phase 2 / Phase 3 |
| Completed | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer NCT04263051 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Completed | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Pa NCT04541706 | Pfizer | Phase 4 |
| Completed | Bronchoscopic Cryo-Immunotherapy of Lung Cancer NCT04049474 | NYU Langone Health | EARLY_Phase 1 |
| Completed | Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC NCT04144608 | Yongchang Zhang | Phase 2 |
| Completed | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology NCT03948724 | Institut Cancerologie de l'Ouest | N/A |
| Terminated | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC NCT04032847 | Achilles Therapeutics UK Limited | Phase 1 / Phase 2 |
| Unknown | Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body R NCT03727867 | Haihua Yang | Phase 3 |
| Completed | Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） NCT03693547 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
| Unknown | Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR NCT03856697 | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Phase 3 |
| Unknown | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and U NCT04239443 | Hunan Cancer Hospital | Phase 2 |
| Completed | RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer NCT03681483 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell L NCT03516981 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer NCT03371485 | Cancer Research UK | Phase 1 |
| Completed | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Pat NCT03351361 | Rennes University Hospital | Phase 3 |
| Completed | D-0316 First Time in Patients Ascending Dose Study NCT03452150 | InventisBio Co., Ltd | Phase 1 |
| Completed | Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC NCT03326752 | Dynavax Technologies Corporation | Phase 1 |
| Completed | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) NCT03014648 | Liza Villaruz, MD | Phase 2 |
| Completed | Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer NCT05380908 | Fifth Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | Multimodality Treatment Including Curative Resection of Advanced NSCLC NCT04455984 | Medical University of Vienna | — |
| Completed | Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. NCT02964689 | Swiss Cancer Institute | Phase 1 |
| Completed | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer NCT03652857 | Yongchang Zhang | Phase 2 |
| Withdrawn | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer NCT02639234 | Gradalis, Inc. | Phase 2 |
| Completed | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer NCT02582125 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formula NCT02163733 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patient NCT02157883 | AstraZeneca | Phase 1 |
| Recruiting | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | AZD9291 in Combination With Ascending Doses of Novel Therapeutics NCT02143466 | AstraZeneca | Phase 1 |
| Terminated | The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab NCT02200354 | Kobe City General Hospital | Phase 2 |
| Completed | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With NCT02108964 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Withdrawn | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer NCT02038699 | Jazz Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer NCT01980212 | Hunan Province Tumor Hospital | — |
| Completed | AZD9291 First Time In Patients Ascending Dose Study NCT01802632 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (C NCT02407327 | Istituto Oncologico Veneto IRCCS | — |
| Completed | Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer NCT01631136 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Completed | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II NCT01649947 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung C NCT03117335 | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. | Phase 3 |
| Completed | Study of Participants With Advanced Non-Small Cell Lung Cancer NCT00948675 | Eli Lilly and Company | Phase 3 |
| Completed | Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients NCT01240447 | Laboratorio Elea Phoenix S.A. | Phase 2 |
| Terminated | Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Can NCT00983047 | Biotech Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) NCT00783471 | Hellenic Cooperative Oncology Group | Phase 2 |
| Unknown | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer NCT00874328 | National Cancer Center, Korea | Phase 1 / Phase 2 |
| Completed | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types NCT00633789 | Bristol-Myers Squibb | Phase 2 |
| Completed | Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer NCT00737867 | The Norwegian Lung Cancer Study Group | Phase 3 |
| Completed | Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer NCT00708812 | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | Phase 2 |
| Unknown | Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC NCT00786331 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 |
| Completed | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer NCT00349219 | National Cancer Institute, Naples | Phase 3 |
| Completed | Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSC NCT00487669 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patie NCT00330746 | National Cancer Institute, Naples | Phase 2 |
| Terminated | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung NCT00345059 | National Cancer Institute, Naples | Phase 3 |
| Completed | Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer NCT00651833 | Taiho Oncology, Inc. | Phase 2 |
| Completed | Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer NCT00652561 | Taiho Oncology, Inc. | Phase 2 |
| Terminated | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression NCT00161278 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC NCT00319514 | Gachon University Gil Medical Center | Phase 2 |
| Completed | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer NCT00072631 | OSI Pharmaceuticals | Phase 2 |
| Completed | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advance NCT00385606 | National Cancer Institute, Naples | Phase 2 / Phase 3 |
| Terminated | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer o NCT00064636 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Available | Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCL NCT06761976 | Bayer | — |